TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05281952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ligation
Description: the surgical ligation of one or both sphenopalatine arteries by endoscopic way.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-selective embolization
Description: occlusion of the terminal branches of the nasal external carotid artery.
Study: NCT05573828

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG angiography to show vascular map of parathyroid glands
Description: Using ICG angiography guided thyroidectomy to identify the vessels feeding the parathyroid glands and then perform the thyroidectomy. After it, ICG angiography is done to predict immediate parathyroid functio
Study: NCT05617443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stackable guide
Description: different types of stackable guide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stackable guide
Description: different types of stackable guide
Study: NCT06392256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival Grafting
Description: In the PM-NS-FGG group, soft tissue augmentation using a free gingival graft will be performed.
Study: NCT06119191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lenses (comfilcon A with current process)
Description: Daily wear lenses for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lenses (comfilcon A with novel process)
Description: Daily wear lenses for 4 weeks
Study: NCT05904106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax plus Azacitidine
Description: Induction cycle 1:~100 mg venetoclax p.o. on day 1; 200 mg venetoclax p.o. on day 2; 400 mg venetoclax p.o. on days 3-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Induction cycles 2-3:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7~Postremission cycles 1-9:~400 mg venetoclax p.o. on days 1-28; 75 mg/m\^2 azacitidine s.c. on days 1-7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care chemotherapy plus gemtuzumab ozogamicin
Description: Induction cycle 1:~200 mg/m\^2 cytarabine cont inf i.v. on days 1-7; 60 mg/m\^2 daunorubicin i.v. on days 3-5; 3 mg/m\^2 (max 1 vial) gemtuzumab ozogamicin i.v. on days 1+4+7~Induction cycle 2 (patients not in remission, moderate or non-responders):~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3; 10 mg/m\^2 mitoxantrone i.v. on days 3-5~Postremission cycles 1-3:~3000/1000 mg/m\^2 cytarabine i.v. BID on days 1-3
Study: NCT06360601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol Injection
Description: Labetalol intravenous infusion 20ml/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HydrALAZINE Injection
Description: Hydralazine intravenous infusion 5mg/hr
Study: NCT06224426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric high-concentration oxygen
Description: During endovascular therapy, eligible participants will receive FiO2=80% through endotracheal intubation, with a gas flow rate set at 4 L/min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric low-concentration oxygen
Description: During endovascular therapy, eligible participants will receive FiO2=30% through endotracheal intubation, with a gas flow rate set at 4 L/min.
Study: NCT05008120

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06523283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural Landscape Pictures Accompanied by Music
Description: after data collection tools filled by participants , they will watch the video one time in hospital bed while breastfeeding , second time in their home while researchers is there and they will also receive the video link so they will contunie to watch video 8 more time. in total 10 sessions will be completed.
Study: NCT05714553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosifloxuridine Nafalbenamide
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosifloxuridine Nafalbenamide
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion
Study: NCT06306053

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: tDCS+EuleriaLab
Description: Home based: Non invasive Neuromodulation treatment + Motor Training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Non invasive brain stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EuleriaLab
Description: Home Motor Training
Study: NCT05677659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGL101
Description: Solution administered via Intravenous Infusion (IV)
Study: NCT05089162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (including the EVEREST, ASCEND and Ambrosy scores) will be performed during day hospitalization or consultation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds
Description: Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds are optional

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: Telephone follow-up will be performed 3, 12 and 24 months after day hospitalization or consultation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study: NCT06556693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual Channel Stimulation
Description: implant of dual channel stimulation device
Study: NCT06310200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Topical 4% Topical Solution
Description: Intranasal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bitrex
Description: Bittering agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo
Study: NCT06055777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SZEY-2108 for injetion
Description: Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1\~D7 and on the morning of D8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SZEY-2108 for injetion
Description: Part1（Single-dose intravenous infusion dose-escalation trial）:100mg，200mg，500mg, 1000mg, 2000mg，4000mg and the dose of last cohort to be determined. Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：1000mg at Q8h，2000mg at Q8h, and one dose level of 1000mg, 1500mg or 2000mg at Q6h. Multiple intravenous doses of SZEY-2108 at Q8h or Q6h on D1\~D7 and on the morning of D8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1\~D7 and on the morning of D8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part1（Single-dose intravenous infusion dose-escalation trial）:250mL/500mL，Single intravenous doses on D1；Part 2（Multi-dose intravenous infusion dose-escalation trial）：250mL,Multiple intravenous doses of placebo at Q8h or Q6h on D1\~D7 and on the morning of D8.
Study: NCT05296629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-29
Description: DFD-29 (40 mg) extended release capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 40 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04990674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMOTION
Description: REMOTION is an internet-based program focusing on emotion regulation and aimed at reducing patient symptom severity and improving emotion regulation. It consists of six modules and the structure is based on the extended process model of emotion regulation by Gross (2015). The intervention is currently being studied in an outpatient psychotherapy setting (Bielinski et al., 2020).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as usual (TAU), refers to standard treatment in an acute inpatient care setting at the Universitäre Psychiatrische Dienste Bern. This treatment includes different standard inpatient psychiatric care components (integrative psychiatric care).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Treatment as usual (TAU), refers to standard treatment in an acute inpatient care setting at the Universitäre Psychiatrische Dienste Bern. This treatment includes different standard inpatient psychiatric care components (integrative psychiatric care).
Study: NCT05311475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone
Description: Mometasone furoate nasal spray (50 mcg per actuation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Mometasone furoate nasal spray (50 mcg per actuation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine
Description: Azelastine hydrochloride nasal spray (140 mcg per actuation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine
Description: Azelastine hydrochloride nasal spray (140 mcg per actuation)
Study: NCT05152615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short Chain Fatty Acids (SCFA) Dietary Supplement
Description: Butryate 1000 mg three times daily will be used in this study.
Study: NCT05389241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method A
Description: The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method B
Description: The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
Study: NCT05311475

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study: NCT05798104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative nurse-pharmacist counseling
Description: At the interventional appointment, study participants will first complete a modified Okere-Reiner pre-survey assessing patient perceptions of confidence and knowledge in their biologic therapy. Subsequently, a pharmacist will perform a refresher medication counseling, detailing indication, dosing, storage, and side effects. Upon completion of this counseling, an infusion nurse will then provide education demonstrating proper self-administration to the patient. The patient will then self-administer the medication with coaching and direct observation from the nurse. Afterwards, the patient will complete the Okere-Reiner post-survey to determine the effectiveness of the counseling session at improving perceived confidence and knowledge. Patients will complete both the pre-and post-surveys with direct entry to REDCap on an institution iPad during the study intervention visit.
Study: NCT04440228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeamSTEPPS
Description: TeamSTEPPS is an evidence-based approach for teams that can be adapted for school mental health.~Team Strategies and Tools to Enhance Performance and Patient Safety (TeamSTEPPS), has been widely disseminated in health care settings with promising outcomes. TeamSTEPPS is designed to build competencies in the areas of leadership, situation monitoring, mutual support, and communication and has been associated with improvements in teamwork and communication as well as patient outcomes, such as decreased seclusion in psychiatric hospitals.
Study: NCT04074954

Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Patients will receive cataract surgery
Study: NCT06492603

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasound is an assessment device that uses high-energy sound waves to look at either superficial tissues like linea alba and/or organs inside the body. The sound waves make echoes that form pictures of the tissues and organs on a computer screen (sonogram).

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasound is an assessment device that uses high-energy sound waves to look at either superficial tissues like linea alba and/or organs inside the body. The sound waves make echoes that form pictures of the tissues and organs on a computer screen (sonogram).

Intervention type: DEVICE
Intervention: The MyotonPRO Device
Description: The MyotonPro is a portable device for measuring biomechanical and viscoelastic properties in superficial soft tissues

Intervention type: DEVICE
Intervention: The MyotonPRO Device
Description: The MyotonPro is a portable device for measuring biomechanical and viscoelastic properties in superficial soft tissues
Study: NCT05079217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dosage SARS-CoV-2 vaccine
Description: SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Medium-dosage SARS-CoV-2 vaccine
Description: SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Study: NCT04978363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BOOT
Description: A walking boot is a common type of brace/boot that restricts ankle and foot movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFC
Description: The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAC
Description: Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFC+BOOT
Description: The Hands Free Crutch (HFC) by iWalkFree, Inc. is a novel, ambulatory assistive device that prevents foot and ankle loading while also allowing free use of the arms and hands. A walking boot is a common type of brace/boot that restricts ankle and foot movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAC+BOOT
Description: Standard axillary crutches (SAC) are ambulatory assistive devices, commonly used for lower extremity injuries or surgeries. A walking boot is a common type of brace/boot that restricts ankle and foot movement.
Study: NCT06087211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine and magnesium sulphate
Description: this group will receive Duloxetine 30 mg orally and an intravenous (IV) infusion of magnesium sulphate 50mg/kg mixed with 200ml normal saline (NS) 1 hour before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: this group will receive Duloxetine 30 mg orally and 200ml NS infusion 1 hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: will receive placebo capsule and an IV infusion of 200ml NS 1 hour before surgery
Study: NCT05020769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is administered at the recommended dose of 80mg daily.
Study: NCT05305040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Posoleucel (ALVR105)
Description: Administered as 2-4 milliliter infusion, visually identical to placebo
Study: NCT06543615

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasound assessment of residual gastric volume

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Ultrasound assessment of residual gastric volume
Study: NCT05892653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABM-1310
Description: Dose Escalation Stage: Subjects will be given oral dosing of ABM-1310 twice daily (BID) for 28-day cycles of continuous administration until progressive disease (PD), unacceptable toxicity, or other withdrawal criteria are met as clinically observed.~Dose Expansion Stage: Subjects will begin to receive oral doses of ABM-1310, BID, for 28-day cycles at a fixed dose level (as determined at the dose escalation stage) until PD, unacceptable toxicity, or other withdrawal criteria are met as clinically observed.
Study: NCT05305040

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
Study: NCT05581134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention
Description: Virtual reality (VR) is a powerful tool to create an illusory state in which the user can feel that they have been transported to a new location (place illusion), that events happening are real (plausibility illusion), and even that bodies have been substituted by an avatar (embodiment illusion). VR illusions are driven by the same neurological mechanisms of everyday perception of the body in the world and induce realistic responses to VR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group intervention
Description: Treatment will follow general treatment principles in physiotherapy for FMDs: (1) education; (2) exploration of how symptoms affect movement and posture; (3) retraining movement using strategies based on redirection of attention; and (4) development of a self-management plan.
Study: NCT05020769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is administered at the recommended dose of 80mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is administered at the recommended dose of 80mg daily.
Study: NCT05374460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explanatory diagram
Description: Participant is told there will be a mismatch between their target finger and the visual indicator of target finger position. They will be shown a diagram explaining this.
Study: NCT04624399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
Study: NCT06356987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Herniotomy
Description: In Group A Laparoscopic assisted needle herniotomy was done
Study: NCT05374460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct vision
Description: Foamboard under mirror removed, making the mirror see-through and the hand directly visible. Mismatch between target hand and visual indicator will be directly visible.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement feedback, target hand
Description: After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will be displaced.
Study: NCT06356987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Herniotomy
Description: In Group A Laparoscopic assisted needle herniotomy was done
Study: NCT05374460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movement feedback, pointing hand
Description: After the participant points at each target, a cursor indicating final pointing position will be displayed briefly. The visual indicator of the target hand will not change, but the cursor indicating pointing hand position will change.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No movement feedback
Description: The visual indicator of the target hand will be displaced, but there will be no cursor to indicate the pointing hand's position.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attend to the targets
Description: Participants will not be told anything about the visuo-proprioceptive mismatch. Instead, they will be asked simply to attend to the target positions.
Study: NCT05015400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain Water
Description: To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
Study: NCT04350866

Intervention type: BEHAVIORAL
Intervention: Brief Behavioral Treatment for Insomnia
Description: An adapted version of Cognitive Behavioral Therapy for Insomnia (CBT-I) that is focused on behavioral components stimulus control and sleep restriction (the four rules):~1. Reduce time awake in bed.~2. Don't go to bed unless ready for sleep.~3. Don't stay in bed unless asleep.~4. Get up and out of bed at the same time everyday.~Delivered weekly to bi-weekly over 4-6 sessions, with each session typically 30 minutes or less, consistent with other interventions delivered in PCMHI.